Follows people with chronic inflammatory nerve disease using Hizentra treatment
Observes how Hizentra is given under the skin in people with chronic inflammatory demyelinating polyneuropathy.
Plain-language title generated from the registry record
Registry title: Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Key facts
- Where
- Amiens, Angers, Aubagne, Bayonne, Bordeaux, Brest, Créteil, Le Kremlin-Bicêtre, Libourne, Lille, Limoges, Lyon, Marseille, Montpellier, Nancy, Nantes, Nice, Paris, Poitiers, Rennes, Rouen, Saint-Etienne, Strasbourg, Toulouse, Tours, and Valence, FranceSee the 27 sites
Where in France
- CHU Amiens Picardie 1Amiens, FranceNot yet recruiting
- CHU AngersAngers, FranceTaking people
- Hôpital privé de La CasamanceAubagne, FranceTaking people
- CH BayonneBayonne, FranceTaking people
- Hopital PellegrinBordeaux, FranceTaking people
- CHRU BrestBrest, FranceTaking people
- Hopital Henri MondorCréteil, FranceTaking people
- Hopital BicetreLe Kremlin-Bicêtre, FranceTaking people
- CH LibourneLibourne, FranceTaking people
- Hopital Roger Salengro, CHU LilleLille, FranceTaking people
- Hopital DupuytrenLimoges, FranceTaking people
- Hôpital Pierre Wertheimer (HCL)Lyon, FranceTaking people
- Hopital de la TimoneMarseille, FranceTaking people
- CHU MontpellierMontpellier, FranceTaking people
- CHRU NancyNancy, FranceTaking people
- CHU NantesNantes, FranceTaking people
- Hopital PASTEURNice, FranceTaking people
- Hôpital LariboisièreParis, FranceTaking people
- La Pitié SalpêtrièreParis, FranceTaking people
- CHU PoitiersPoitiers, FranceTaking people
- Centre hospitalier privé Saint GrégoireRennes, FranceTaking people
- Hôpital Charles NicolleRouen, FranceTaking people
- CHU Saint-EtienneSaint-Etienne, FranceTaking people
- CHU de StrasbourgStrasbourg, FranceNot yet recruiting
- CHU ToulouseToulouse, FranceNot yet recruiting
- CHR ToursTours, FranceTaking people
- CH de ValenceValence, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CSL Behring
- Trial code
- NCT04672733
- Record updated
- 7 January 2025
- Original description
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).Read full original descriptionShow less
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).
Inclusion: Adult patient (aged ≥18 years); Patients suffering from CIDP according to EAN/PNS 2021 criteria; Planned switch from IVIg to Hizentra®; Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins; Patient deemed to be stable, with no change in their treatment for the disease during the 3 months prior to inclusion; Patients who have a smartphone, a tablet or a computer; Patients who have been informed verbally and in writing of the purposes of the study.
Exclusion: Concomitant participation in an interventional clinical study.